explore -WSS

explore

author：explore 2025-09-30 17:29:10 - browse：786

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Feng Zhang CRISPR delivery startup lays off quarter of staff

WSS

The FDA must approve intranasal treatments for anaphylaxis

J&J to buy cancer drug developer Ambrx Biopharma

Curing rare childhood diseases will falter unless Congress steps up

Statins may not be needed by millions of people, study suggests

Study: Why relieving medical debt did not improve financial outcomes

How a scoliosis diagnosis changed the life of one young dancer

knowledge

explore

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The system is set up to fail children with medical complexity

As demand for Covid shots wanes, Moderna seeks its next success

Study: Why relieving medical debt did not improve financial outcomes

Peter Hotez and the public health issue of online harassment

Burning questions for the 2024 JPM Healthcare Conference

Novavax promises a turnaround & Lilly roils the obesity market

GSK Flovent asthma inhalers replaced by authorized generics

Jerome Adams on the need for new antivirals for Covid

Coercive sterilizations revealed by STAT prompt outrage

explore

UCB departs biotech trade group BIO

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Burning questions for the 2024 JPM Healthcare Conference

Pharma companies must ensure equitable access to obesity drugs

Videos point to link between seizures and unexplained toddler deaths

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

hotspot

hotspot

focus

focus